Navigation Links
XYOTAX More Cost Effective With Fewer Side Effects Than Gemcitabine,or Vinorelbine in Treating Non-Small Cell Lung Cancer

ASCO publication highlights health care cost benefit of bioengineering paclitaxel

CHICAGO, June 05, 2007 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) announced that data published in the 2007 Annual Meeting of the American Society of Clinical Oncology (ASCO) abstracts showed reduced medical resource utilization (MRU) and associated costs with XYOTAX (paclitaxel polyglumex) treatment compared to gemcitabine or vinorelbine in treating patients with non-small cell lung cancer (NSCLC). The total average treatment cost, excluding drug costs, for XYOTAX patients was nearly half the cost of treatment for patients on standard chemotherapy ($2,518 vs. $4,834 per patient) and was associated with a significant reduction in many of the toxic side effects.

"This analysis shows XYOTAX, when used as a single agent and compared with standard single agent therapy with either gemcitabine or vinorelbine in NSCLC patients, had comparable efficacy as measured by overall survival. But notably, patients treated with XYOTAX had a clinical benefit in its side effect profile, and a substantial cost advantage over the standard agents," said Jack W. Singer, M.D., Chief Medical Officer of CTI. "These are important data in support of the clinical benefits associated with XYOTAX."

Medical Resource Utilization (MRU) and Costs Associated with XYOTAX(TM) (paclitaxel poliglumex; PPX) Compared to Gemcitabine (Gem) or Vinorelbine (Vin) In Non-Small Cell Lung Cancer (NSCLC) Patients (Abstract #18172)

MRU data were collected as part of a multinational, randomized trial (STELLAR 4) that compared XYOTAX (n=191) to gemcitabine or vinorelbine (n=190) in patients with advanced NSCLC who had not previously received chemotherapy and who had poor performance status (PS2). MRU and costs associated with chemotherapy administration and non-protocol-driven care were compared over the study period.

The results showed patien
'"/>




Page: 1 2 3 4

Related medicine technology :

1. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
2. Eurands Zentase Effective in Treating Exocrine Pancreatic Insufficiency, Studies Show
3. Cimzia Effective in Reducing Signs and Symptoms of Rheumatoid Arthritis
4. Gabapentin Shown Effective for Fibromyalgia Pain
5. ApoCells Cancer Predictive Index Helps Oncologists Select the Most Effective Targeted Drug Therapy
6. Roxro Pharma’s Novel Intranasal Pain Reliever Effective, Well Tolerated in Phase 3 Study
7. Soliris Effective in PNH Patients With History of Aplastic Anemia and Myelodysplastic Syndromes
8. Repeated Radioimmunotherapy With 131I-Labetuzumab Appears Safe and Effective in Colorectal Cancer with Liver Metastases
9. Biotheras Imprime PGG Enhanced Effectiveness of Avastin in Cancer Study
10. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
11. In New Study, Duloxetine Was Equally Effective, Regardless of Switch Method, in Reducing Painful Symptoms in Ssri Non- or Partial-responders with Depression
Post Your Comments:
(Date:10/9/2008)...lts Expected in November 2008, BOTHELL, Wash., Oc...(Amex: DDD ) announced today the completion of pa...hree pivotal trials to evaluate the safety and,eff...se (ER) ibuprofen for,the over-the-counter (OTC) m...lts from this pivotal trial in November 2008. Ibup...
(Date:10/8/2008)...8 /PRNewswire-USNewswire/ -- The facts are,overwhe.../AIDS in,sub-Saharan Africa. More than 35,000,000 ...e already died of AIDS. The Foundation for Hospice...ying and their families,find compassion and relief...tive partnering initiative links African hospices ...
(Date:10/8/2008)...e Pioneers Research That May Offer New Hope to,Hea... -- Nationally, over 3,000 people are,waiting for ...y, only half,of those will receive a transplant. N... (AHI) is paving the way for how to treat congesti...timedia News Release, go to:, http://www.prnewswir...
(Date:10/8/2008)...o evaluate TAXUS(R) Element(TM) Platinum Chromium ...ss., Oct. 8 /- Boston Scien...at it has completed enrollment in,the PERSEUS tria...tion,TAXUS(R) Element(TM) paclitaxel-eluting coron...ed nearly 1,500 patients at 100 U.S. and,internati...
Breaking Medicine Technology:SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 2SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 2Video: Answer to Curing a Failing Heart May Exist in Body's Own 'Do-It-Yourself' Repair Kit 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 2Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 3Boston Scientific Completes Clinical Trial Enrollment for Third-Generation Drug-Eluting Stent 4LS9 Inc the Renewable Petroleum Company 28TM 29 Adds Key Positions to Executive Team and Scientific Advisory Board 3073 1LS9 Inc the Renewable Petroleum Company 28TM 29 Adds Key Positions to Executive Team and Scientific Advisory Board 3073 2Innovative eHealth Course to Take Place March 28 30 in Boston Massachusetts 11142 1Innovative eHealth Course to Take Place March 28 30 in Boston Massachusetts 11142 2Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 1Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 2Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 3Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 4Intensive blood sugar treatment in trial of diabetes and cardiovascular disease changed 11138 5Tropical soils impede landmine detection 2134 1Tropical soils impede landmine detection 2134 2
...mboEmbolism (VTE) is Reduced by a,Significant 43% ...xane(R) / Lovenox(R), BRIDGEWATER, N.J., April 20,...ounced the publication of the PREVAIL (Prevention,...parin) trial in,the April 21st issue of The Lancet...administration of Clexane(R) / Lovenox(R),(enoxapa...
... Clinical Potential of Peregrine,s,Unique Selectiv...,Avastin(R) in Animal Cancer Models, TUSTIN, Calif...ine Pharmaceuticals, Inc. , a clinical stage,bioph...l antibodies,for the treatment of cancer and hepat...rom multiple studies presented at the recent,Cente...
Other Medicine Technology:The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 2The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 3The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 4The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 5The Lancet Publishes PREVAIL Study Results Showing Lovenox,Superiority Over Unfractionated Heparin for Reducing the Risk of,Venous ThromboEmbolism in Patients With Acute Ischemic Stroke 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 2Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 3Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 4Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 5Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 6Peregrine Pharmaceuticals Highlights Significant Advances in the,Company's Clinical and Preclinical Cancer Programs Presented This,Week at the AACR Annual Meeting 7
(Date:10/12/2008)... Birdstep Technology,s high availability embedded ...carrier grade OSE RTOS. , ...Technology (OSE: BIRD) today announced the release...ing system. This is the latest platform to be adde...d platforms., , ,"We recognized the importanc...
(Date:10/11/2008)...ould Not Pose Setback and Expects the 89-Year-Old ... ASHEVILLE, N.C., Oct. 11 /PRNewswire/ -- Evangeli...in Montreat, N.C. upon his release this,afternoon ...g a brief stay.,He was admitted for observation af... late Friday., Mr. Graham,s physicians said that ...
(Date:10/11/2008)...ernational Transcends Cultural Divides, JOHANNESB...frican and,international audiences welcome Bishop ...fying gathering, which for the first time is being...tp://www.newscom.com/cgi-bin/prnh/20081011/CLSA011...off with performances by,South Africa,s own multi-...
(Date:10/10/2008)... those already on drugs, some diagnoses could be w...althDay News) -- A new study questions the commonl...e ( C. difficile ) infections are always preceded ...iversity and the Jewish General Hospital found tha...cquired C. difficile infections before hospitali...
Breaking Medicine News(10 mins):Health News:Birdstep Technology Adds ENEA's OSE RTOS to the List of Operating Systems Supported by Their RDM Server, Embedded Database Product 2Health News:Billy Graham Returns Home Following Hospital Observation 2Health News:Bishop T.D. Jakes Electrifies South Africa 2Health News:Antibiotics May Not Cause Diarrheal Bacteria 2
...yan governmment said Tuesday the rate of HIV/AIDS ...e still posed a a major challenge in the country....CC) said the rate fell from 6.1 percent in 2004 to...nt of the country's nearly 35 million people. "Of...
...etic version of a molecule found in the egg cells ...provide the world with the first drug treatment fo...es the sugary coating found on a tumour cell and b... invading the cell and inactivating the RNA it con...
...s is understood as the perception of noise in the ...nal source of sound, without any vibratory cochlea...rnal noise is produced). It is estimated that bet...uffered tinnitus at some time in their lives, acco...
...t study has found that a substance derived from th...rtain kinds of cancer cells. The study, conducte...ested that this substance could lead to a novel tr...mmon type of lung cancer. The compound, called be...
Other Medicine News:Health News:Brain Tumor Drug in Frogs A New Report 2Health News:Tinnitus Patients can Lead a Normal Life 2Health News:Tinnitus Patients can Lead a Normal Life 3Health News:Tinnitus Patients can Lead a Normal Life 4Health News:Tinnitus Patients can Lead a Normal Life 5Health News:Tree Bark Substance may Hold New Lung-cancer Treatment 2
Restylane is a gel of hyaluronic acid generated by,Streptococcus species of bacteria, chemically crosslinked,with BDDE, stabilized and suspended in phosphate,buffered saline at pH = 7 and concentrati
SCULPTRA™ is an injectable implant that contains microparticles of poly-L-lactic acid, a biocompatible, biodegradable, synthetic polymer from the alpha-hydroxy-acid family. SCULPTRA is reconsti
The HEMOCHRON Response is a whole blood coagulation monitoring instrument designed to be used at the point-of-care. The Response includes an easy-to-read screen and data management features, includin
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo
Medicine Products: